Avenue Therapeutics to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

Core Viewpoint - Avenue Therapeutics, Inc. is actively engaged in the development and commercialization of therapies for neurologic diseases, with a focus on presenting its advancements at industry conferences [1][2]. Group 1: Company Overview - Avenue Therapeutics, Inc. is a specialty pharmaceutical company listed on Nasdaq under the ticker ATXI [2]. - The company is headquartered in Miami, Florida, and was founded by Fortress Biotech, Inc. [2]. Group 2: Product Development - Avenue Therapeutics is developing three key assets: - AJ201, a first-in-class treatment for spinal and bulbar muscular atrophy [2]. - BAER-101, an oral small molecule selective GABAA α2, α3 receptor positive allosteric modulator targeting CNS diseases [2]. - IV tramadol, which is currently in Phase 3 clinical development for managing acute post-operative pain in adults within medically supervised healthcare settings [2]. Group 3: Upcoming Events - Alexandra MacLean, M.D., the CEO of Avenue Therapeutics, will present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference, with the presentation available for on-demand viewing starting June 27, 2024, at 7:00 a.m. ET [1].